Peak6 Investments LLC Sage Therapeutics, Inc. Transaction History

Peak6 Investments LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $100,500 - $293,880	6,000 Added 66.67%	15,000 $308,000
Q2 2023 Aug 11, 2023	BUY	$40.65 - $59.54 $194,510 - $284,898	4,785 Added 113.52%	9,000 $423,000
Q1 2023 May 12, 2023	BUY	$37.27 - $46.57 $39,878 - $49,829	1,070 Added 34.02%	4,215 $176,000
Q4 2022 Feb 10, 2023	BUY	$32.2 - $43.61 $101,269 - $137,153	3,145 New	3,145 $120,000
Q1 2020 May 14, 2020	SELL	$26.15 - $77.24 $87,367 - $258,058	-3,341 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $180,178 - $463,381	2,994 Added 862.82%	3,341 $241,000
Q3 2019 Nov 08, 2019	BUY	$140.29 - $189.96 $14,870 - $20,135	106 Added 43.98%	347 $49,000
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $32,517 - $37,716	-206 Reduced 46.09%	241 $44,000
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $66,550 - $121,919	-745 Reduced 62.5%	447 $71,000
Q4 2018 Feb 13, 2019	BUY	$81.94 - $139.71 $68,665 - $117,076	838 Added 236.72%	1,192 $114,000
Q3 2018 Nov 13, 2018	BUY	$138.11 - $169.04 $48,890 - $59,840	354 New	354 $50,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Peak6 Investments LLC with notifications on news.